STAT3 and neoplasm: Recently, a preclinical study evaluated the combined effects of an anti-PD-1 antibody with a STAT3 inhibitor (STX-0119) in an in vivo pancreatic cancer model; however, no significant anti-tumor benefits were observed and the study was terminated due to safety concerns from excessive weight loss [51].